DKC1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Molibresib (SCHEMBL1872390)	1.00	1/20
Molibresib (SCHEMBL12671490)	1.00	1/20
Molibresib (SCHEMBL12966358)	1.00	1/20
SCHEMBL9998851	0.91	1/20
SCHEMBL14756282	0.88	1/20
SCHEMBL15980874	0.88	1/20
SCHEMBL12966165	0.87	1/20
SCHEMBL14756215	0.87	1/20
SCHEMBL14756339	0.87	1/20
SCHEMBL15980861	0.87	1/20
SCHEMBL9998825	0.86	1/20
SCHEMBL15980893	0.86	1/20
SCHEMBL15980803	0.86	1/20
SCHEMBL1874116	0.85	1/20
SCHEMBL12671221	0.85	1/20
SCHEMBL14756021	0.85	1/20
SCHEMBL14756240	0.85	1/20
SCHEMBL14756287	0.85	1/20
SCHEMBL14756335	0.85	1/20
SCHEMBL14756409	0.85	1/20

Clinical trials — most relevant to DKC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Nandrolone Decanoate in the Treatment of Telomeropathies	PHASE1/PHASE2	COMPLETED
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer	PHASE1	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	ACTIVE_NOT_RECRUITING
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
CDH1 Germline Mutations in Lobular Breast Cancer	nan	COMPLETED
Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity	nan	COMPLETED
Genetics of Primary Ciliary Dyskinesia	nan	COMPLETED
Telomere Repair Gene Mutation in Inflammatory Bowel Disease	nan	COMPLETED
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Exome Analysis in Hearing Impaired Patients	nan	UNKNOWN
RDC Biomarker Study	nan	RECRUITING
Genetic Study of Patients With Primary Ciliary Dyskinesia	nan	COMPLETED
Early Check: Expanded Screening in Newborns	nan	ENROLLING_BY_INVITATION
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study	nan	RECRUITING
Evaluation of Brain Dysfunction in Patients with Duchene Muscular Dystrophy	nan	NOT_YET_RECRUITING
Interest of High-throughput Sequencing of RNAs for the Diagnosis of Heterogeneous Genetic Diseases	nan	UNKNOWN
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia	nan	COMPLETED
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.	nan	COMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma	nan	RECRUITING
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions	nan	RECRUITING
Mutational Landscape in Hepatocellular Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a DKC1 binder may also engage these)

Protein	Name	Similarity
Q5ZJH9	—	1.000	Q5ZJH9 →
Q9ESX5	—	0.998	Q9ESX5 →
O43100	—	0.994	O43100 →
O43102	—	0.992	O43102 →
F1Q749	—	0.992	F1Q749 →
P40615	—	0.991	P40615 →
O14007	—	0.986	O14007 →
Q9LD90	—	0.982	Q9LD90 →
O43101	—	0.975	O43101 →
P33322	—	0.970	P33322 →
O13473	—	0.969	O13473 →
G0SGK0	—	0.968	G0SGK0 →
Q7ZWS1	—	0.962	Q7ZWS1 →
Q9SIZ2	—	0.962	Q9SIZ2 →
A0A0G2KTI4	—	0.961	A0A0G2KTI4 →
O44081	—	0.960	O44081 →
UBA2	SUMO-activating enzyme subunit 2	0.959	landscape →
Q28BT8	—	0.959	Q28BT8 →
P32481	—	0.957	P32481 →
O48556	—	0.956	O48556 →
Q5R6E0	—	0.955	Q5R6E0 →
Q9Z1F9	—	0.955	Q9Z1F9 →
O59948	—	0.955	O59948 →
SLC12A2	Solute carrier family 12 member 2	0.955	landscape →
A4FUD3	—	0.954	A4FUD3 →
P55012	—	0.953	P55012 →
Q5F3X4	—	0.953	Q5F3X4 →
Q9QW07	—	0.953	Q9QW07 →
Q7QG73	—	0.953	Q7QG73 →
Q642Q1	—	0.953	Q642Q1 →